IPO - Lexeo Therapeutics, Inc.

Form Type: 424B5

Filing Date: 2025-03-24

Corporate Action: Ipo

Type: New

Accession Number: 000119312525060883

Filing Summary: Lexeo Therapeutics, Inc. is conducting a public offering of its common stock with an aggregate offering price of up to $75 million. The Sales Agreement with Leerink Partners LLC allows the company to sell shares on an ‘at-the-market’ basis, which means no specific number is guaranteed. As of the closing price on March 21, 2025, the shares are priced at $2.71 each. The company aims to use the proceeds from this offering for general corporate purposes, which could include clinical trials, research and development, and potentially acquisitions. Lexeo is a clinical-stage genetic medicine company focusing on cardiovascular diseases, with key products in trials, including LX2006 and LX2020, both targeting serious heart conditions. The document highlights the risks involved in investing in their securities while also noting the company's status as an emerging growth company, which significantly eases certain reporting requirements. There is no state or SEC approval regarding the adequacy of this prospectus supplement. The risks of the investment include potential dilution of stock value and reliance on management's discretion for the use of offering proceeds.

Document Link: View Document